^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PORCN inhibitor

    Related drugs:
    Apply
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (NCT01351103)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/01/2011
    Primary completion :
    06/14/2021
    Completion :
    06/18/2024
    BRAF • RNF43
    |
    BRAF mutation • RNF43 mutation
    |
    spartalizumab (PDR001) • WNT974
    A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) (PORCUPINE) (NCT04907539)
    Phase 2
    Redx Pharma Plc
    Completed
    Last update posted :
    05/03/2024
    Initiation :
    11/08/2021
    Primary completion :
    04/02/2024
    Completion :
    04/02/2024
    RNF43 • RSPO2
    |
    Opdivo (nivolumab) • Prolia (denosumab) • zamaporvint (RXC004)
    A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) (NCT04907851)
    Phase 2
    Redx Pharma Plc
    Completed
    Last update posted :
    03/08/2024
    Initiation :
    12/10/2021
    Primary completion :
    11/30/2023
    Completion :
    11/30/2023
    RNF43
    |
    RNF43 mutation
    |
    Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)
    A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours (NCT02521844)
    Phase 1
    EDDC (Experimental Drug Development Centre), A*...
    Active, not recruiting
    Last update posted :
    11/08/2023
    Initiation :
    10/01/2015
    Primary completion :
    02/01/2024
    Completion :
    05/01/2024
    RSPO2 • RSPO3
    |
    RSPO3 fusion
    |
    Keytruda (pembrolizumab) • ETC-159
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (NCT02675946)
    Phase 1b
    Curegenix Inc.
    Recruiting
    Last update posted :
    01/26/2022
    Initiation :
    02/01/2016
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
    |
    BRAF V600E • BRAF V600
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321
    Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (NCT02278133)
    Phase 1/2
    Array BioPharma
    Completed
    Last update posted :
    10/09/2017
    Initiation :
    12/01/2014
    Primary completion :
    05/31/2016
    Completion :
    06/23/2017
    KRAS • RNF43
    |
    KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974